New Diagnostic Blood Test Developed for Concussions (eHealth News)
UF biotech company, Banyan Biomarkers, Inc. has developed the first blood test that can be used by physicians to objectively aid in the evaluation of patients with suspected traumatic brain injury (TBI) or concussions. Banyan is a University of Florida startup and a graduate of UF Innovate | Sid Martin Biotech. The Banyan Brain Trauma Indicator® […]
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medi (BioFlorida)
UF startup and Sid Martin Biotech alum Ology Bioservices, Inc., a biologics contract development and manufacturing organization, and Rafa Laboratories, Ltd., a leading Israeli pharmaceutical company, announced that on July 9, 2018, they received full approval from the U.S. Food and Drug Administration (FDA) for the Atropine Injection, 2mg/0.7mL, Single-Dose Autoinjector. The Atropine Autoinjector initially […]
AxoGen, Inc Common Stock (AXGN) Sets New 1-Year High at $56.85 (Fairfield Current)
UF startup and Sid Martin Biotech alum AxoGen, Inc reported that its Common Stock (NASDAQ:AXGN) shares hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $56.85 and last traded at $54.90, with a volume of 4762 shares changing hands. The stock had previously closed at $56.60. The company […]
AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone (BioFlorida)
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has enrolled the first patient of the second cohort in the company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the […]
Captozyme Initiates Clinical Study of Nephure™ Oxalate-Reducing Enzyme (BusinessWire)
UF Innovate incubator graduate Captozyme, Inc. announced that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure™, an oxalate reducing enzyme, to determine the extent to which Nephure vs. placebo reduces urinary oxalate excretion (mg/24 hour) in healthy subjects who are provided a controlled diet. Captozyme is a graduate of both […]
Assembly Biosciences Initiates Phase 2a Trial for HBV Core Inhibitor (Healio)
UF Innovate | Sid Martin Biotech alumni company Assembly Bioscience announced the initiation of two randomized control phase 2a trials for ABI-H0731, the company’s lead hepatitis B core inhibitor, according to a press release. ABI-H0731 previously demonstrated potent antiviral activity in a phase 1b trial, the results of which were presented at the International Liver […]
Explain Your Brain: New Breakthroughs In TBI Science For Veterans (DisabledVeterans.org)
(This post on DisabledVeterans.org discusses traumatic brain injury and calls the blood test that indicates TBI created by UF startup & Sid Martin Biotech graduate Banyan Biomarkers “great news.”) If you’re a veteran with a traumatic brain injury, or TBI, you know how frustrating it can be. With a range of types and severities, TBI […]
AxoGen CEO Karen Zaderej Named A Florida Entrepreneur of the Year (BioSpace)
As a female chief executive officer in the healthcare industry CEO Karen Zaderej often stands out in a male-dominated industry. This month she stood out for another reason – as the Ernst & Young Entrepreneur of the Year 2018 Award winner for the state of Florida in the healthcare category. Zaderej leads AxoGen, a UF […]
Nematodes in Space – Pheronym Wins Grant for Eco-Friendly Pest Control for Interstellar Agriculture (EIN Newsdesk)
Pheronym, a bio-ag-tech pest control company that is a client of UF Innovate | Sid Martin Biotech and a former client of The Hub, has received the Florida-Israel Innovation Partnership Award for its nematode focused pest control solution. The $300,000 award will help the company conduct field tests of its proprietary eco-friendly solution with a […]
Oragenics Touts New Drug to Fight Clostridium Difficile (Proactive Investors)
New research by Sid Martin Biotech alum Oragenics Inc., now a Tampa-based clinical-stage biotech group, has uncovered a novel type of antibiotic known as a lantibiotic for the treatment of clostridium difficile, an infection causing colitis, called OG716. When golden Syrian hamsters infected with clostridium difficile were treated with the drug OG716, a variant of […]